Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.41%KO-0.71%0700.HK-6.57%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK+0.05%ORCL-0.97%3988.HK-0.60%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.80%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.03%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.51%AUDUSD-1.44%AUDCAD-0.86%AUDNZD-0.86%EURAUD+0.85%AUDCHF-0.84%GBPAUD+0.79%GBPJPY-0.72%EURJPY-0.69%CHFJPY-0.67%NZDJPY-0.66%CADJPY-0.65%USDCHF+0.64%GBPUSD-0.64%EURUSD-0.61%USDCAD+0.60%NZDUSD-0.58%AUDSGD-0.49%USDZAR+0.45%GBPTRY+0.41%AUDDKK-0.41%USDTHB+0.35%GBPHKD+0.32%AUDNOK-0.31%NZDMXN+0.31%USDMXN+0.30%GBPMXN-0.28%EURZAR+0.28%USDNOK+0.26%GBPZAR+0.26%USDSEK+0.22%USDPLN+0.21%USDTRY+0.21%EURCNH-0.19%CHFNOK+0.17%EURHKD-0.17%USDDKK+0.17%USDILS+0.16%CHFSEK+0.13%NOKJPY-0.12%USDCNH-0.11%NZDSGD+0.11%EURNOK+0.10%GBPSGD-0.10%EURSGD-0.09%USDJPY-0.08%USDSGD+0.08%SGDJPY+0.07%GBPCAD-0.07%PLNJPY-0.07%EURSEK+0.06%GBPNZD-0.06%EURPLN+0.05%EURGBP+0.04%CADCHF+0.04%USDCOP-0.04%EURCZK+0.04%EURCHF+0.04%NZDCHF+0.03%EURNZD-0.03%CHFSGD-0.02%EURCAD-0.02%NZDCAD-0.01%USDHKD-0.01%GBPCHF0.00%EURDKK0.00%XPTUSD-0.68%XNGUSD-0.60%W1-0.47%UKOIL+0.42%C1-0.40%GAUUSD-0.28%XAUUSD-0.28%S1-0.24%XAGUSD-0.17%GAGUSD-0.17%HG1-0.12%USOIL+0.11%BTCUSD-2.78%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+1.03%ZECUSDT-5.36%XMRUSDT-1.52%DOGEUSD+55.95%LINKUSD-2.51%XLMUSD-3.01%BCHUSDT-2.75%LTCUSD+47.50%UNIUSD-2.19%SUIUSD-1.87%TONUSD+59.18%HBARUSDT-4.33%TAOUSDT-1.88%AAVEUSD-2.46%ONDOUSDT-3.78%ICPUSDT-1.61%DOTUSDT-2.96%WLDUSDT-2.45%ARBUSDT-4.84%ATOMUSDT-1.49%INJUSDT-6.37%STXUSDT-1.32%PYTHUSDT+1.09%TIAUSDT-1.70%FETUSDT-3.49%JUPUSDT+1.77%SEIUSDT-2.00%GRTUSDT-2.55%OPUSDT-2.63%IOTAUSDT-1.46%POLUSDT-1.33%WIFUSDT-2.25%AXSUSDT-2.04%EOSUSDT-3.45%IMXUSDT-3.36%FARTCOINUSDT-5.36%GALAUSDT-1.65%DYDXUSDT-1.92%ORDIUSDT-1.56%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.41%KO-0.71%0700.HK-6.57%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK+0.05%ORCL-0.97%3988.HK-0.60%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.80%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.03%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.51%AUDUSD-1.44%AUDCAD-0.86%AUDNZD-0.86%EURAUD+0.85%AUDCHF-0.84%GBPAUD+0.79%GBPJPY-0.72%EURJPY-0.69%CHFJPY-0.67%NZDJPY-0.66%CADJPY-0.65%USDCHF+0.64%GBPUSD-0.64%EURUSD-0.61%USDCAD+0.60%NZDUSD-0.58%AUDSGD-0.49%USDZAR+0.45%GBPTRY+0.41%AUDDKK-0.41%USDTHB+0.35%GBPHKD+0.32%AUDNOK-0.31%NZDMXN+0.31%USDMXN+0.30%GBPMXN-0.28%EURZAR+0.28%USDNOK+0.26%GBPZAR+0.26%USDSEK+0.22%USDPLN+0.21%USDTRY+0.21%EURCNH-0.19%CHFNOK+0.17%EURHKD-0.17%USDDKK+0.17%USDILS+0.16%CHFSEK+0.13%NOKJPY-0.12%USDCNH-0.11%NZDSGD+0.11%EURNOK+0.10%GBPSGD-0.10%EURSGD-0.09%USDJPY-0.08%USDSGD+0.08%SGDJPY+0.07%GBPCAD-0.07%PLNJPY-0.07%EURSEK+0.06%GBPNZD-0.06%EURPLN+0.05%EURGBP+0.04%CADCHF+0.04%USDCOP-0.04%EURCZK+0.04%EURCHF+0.04%NZDCHF+0.03%EURNZD-0.03%CHFSGD-0.02%EURCAD-0.02%NZDCAD-0.01%USDHKD-0.01%GBPCHF0.00%EURDKK0.00%XPTUSD-0.68%XNGUSD-0.60%W1-0.47%UKOIL+0.42%C1-0.40%GAUUSD-0.28%XAUUSD-0.28%S1-0.24%XAGUSD-0.17%GAGUSD-0.17%HG1-0.12%USOIL+0.11%BTCUSD-2.78%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+1.03%ZECUSDT-5.36%XMRUSDT-1.52%DOGEUSD+55.95%LINKUSD-2.51%XLMUSD-3.01%BCHUSDT-2.75%LTCUSD+47.50%UNIUSD-2.19%SUIUSD-1.87%TONUSD+59.18%HBARUSDT-4.33%TAOUSDT-1.88%AAVEUSD-2.46%ONDOUSDT-3.78%ICPUSDT-1.61%DOTUSDT-2.96%WLDUSDT-2.45%ARBUSDT-4.84%ATOMUSDT-1.49%INJUSDT-6.37%STXUSDT-1.32%PYTHUSDT+1.09%TIAUSDT-1.70%FETUSDT-3.49%JUPUSDT+1.77%SEIUSDT-2.00%GRTUSDT-2.55%OPUSDT-2.63%IOTAUSDT-1.46%POLUSDT-1.33%WIFUSDT-2.25%AXSUSDT-2.04%EOSUSDT-3.45%IMXUSDT-3.36%FARTCOINUSDT-5.36%GALAUSDT-1.65%DYDXUSDT-1.92%ORDIUSDT-1.56%NOTUSDT+0.86%RONINUSDT-2.92%
FT

Fate Therapeutics, Inc. (FATE)

NASDAQ • Healthcare

$1.05
+$0.03 (+2.9%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$1.06
Day Range$1.02 - $1.08
Avg. Volume (3M)1.6M
Market Cap$122.3M
52 Week Range
$0.95$3.23

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$4.7M
Net Income (TTM)
-$124.4M
EPS (TTM)
-$1.03
ROA (TTM)
-52.22%
Current Ratio
4.41

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+10.3%Q2 2026-$0.26
+1.4%Q3 2026-$0.25
+7.4%Q4 2026-$0.25

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +7.4%

Fate Therapeutics topped expectations on EPS in the third fiscal quarter of 2026, and based on preliminary results reported November 5, 2026 it posted EPS of -$0.25 versus the -$0.27 estimate (difference $0.02), improving ~7% year over year from -$0.27 as the clinical-stage cellular immunotherapy developer continued to run its NK- and T-cell immuno-oncology pipeline without marketed-product revenue as a primary driver. Net loss narrowed to about $30.7 million, a ~5% year-over-year improvement from roughly $32.2 million a year ago, while operating loss was about $32.2 million for the quarter. Cash flow remained negative, with negative operating cash flow of roughly $27.9 million, reflecting ongoing R&D and operating spend tied to advancing programs such as FT516, FT596, FT538, and FT576. For the next period, consensus calls for EPS of -$0.28 on revenue of $1.1 million.

View full earnings history

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing programmed cellular immunotherapies for cancer. The company works in the healthcare sector as a clinical-stage drug developer, with a pipeline centered on NK- and T-cell immuno-oncology programs rather than marketed products.

Name
Fate Therapeutics, Inc.
CEO
Bahram Valamehr
Industry
Healthcare
Year Founded
2007
Employees
161

Today's Snapshot

AI-generated

FATE closed 2.9% higher at 1.05, outperforming a weaker sector. Fate Therapeutics outlined broader use for CAR T-cell therapy, which trains immune cells to fight cancer.

Trading Volume

Below 10d avg (2.4M)

1.8M

vs S&P 500 Today

Strong Outperformance

+3.20%

Updated: November 18, 2026 at 21:26 UTC

Technical Indicators

2 Buy0 Neutral6 Sell
FATE demonstrates pronounced downside characteristics, with price sitting well under its short-, medium- and long-term moving averages and both CCI and MACD in negative territory, indicating selling pressure. Several momentum measures read as deeply oversold even as ADX implies a modest trending environment, and volatility is high relative to price, which can accentuate moves lower; on-balance volume also reads as bearish. The classic pivot aligns with the market but does not offset the breadth of negative signals across averages and momentum. Technical takeaway: Strong Sell — broad technical deterioration with elevated volatility and bearish volume.
All signals
  • EMA (5 indicators)$1.41 - $2.08
    Sell
  • RSI (14)20.90
    Buy
  • Stochastic %K (14, 3, 3)2.02
    Buy
  • MACD Level (12, 26)-0.27
    Sell

Peers & Related Assets

ALECAlector, Inc.
$2.57+0.4%
NKTXNkarta, Inc.
$1.15-8.0%
VORVor Biopharma Inc.
PEPGPepGen Inc.
PRLDPrelude Therapeutics Incorporated
INOInovio Pharmaceuticals, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.